|
1
|
Gracia-Sancho J, Casillas-Ramirez A and
Peralta C: Molecular pathways in protecting the liver from
ischaemia/reperfusion injury: a 2015 update. Clin Sci (Lond).
129:345–362. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Saidi RF and Kenari SK: Liver
ischemia/reperfusion injury: an overview. J Invest Surg.
27:366–379. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jaeschke H: Mechanisms of Liver Injury.
II. Mechanisms of neutrophil-induced liver cell injury during
hepatic ischemia-reperfusion and other acute inflammatory
conditions. Am J Physiol Gastrointest Liver Physiol.
290:G1083–G1088. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nastos C, Kalimeris K, Papoutsidakis N,
Tasoulis MK, Lykoudis PM, Theodoraki K, Nastou D, Smyrniotis V and
Arkadopoulos N: Global consequences of liver ischemia/reperfusion
injury. Oxid Med Cell Longev. 2014(906965)2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Thorgersen EB, Barratt-Due A, Haugaa H,
Harboe M, Pischke SE, Nilsson PH and Mollnes TE: The role of
complement in liver injury, regeneration, and transplantation.
Hepatology. 70:725–736. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhou Y, Zhang J, Lei B, Liang W, Gong J,
Zhao C, Yu J, Li X, Tang B and Yuan S: DADLE improves hepatic
ischemia/reperfusion injury in mice via activation of the Nrf2/HO-1
pathway. Mol Med Rep. 16:6214–6221. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lu L, Zhou H, Ni M, Wang X, Busuttil R,
Kupiec-Weglinski J and Zhai Y: Innate immune regulations and liver
ischemia-reperfusion injury. Transplantation. 100:2601–2610.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jaeschke H, Farhood A, Bautista AP,
Spolarics Z and Spitzer JJ: Complement activates Kupffer cells and
neutrophils during reperfusion after hepatic ischemia. Am J
Physiol. 264:G801–G809. 1993.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Arumugam TV, Woodruff TM, Stocks SZ,
Proctor LM, Pollitt S, Shiels IA, Reid RC, Fairlie DP and Taylor
SM: Protective effect of a human C5a receptor antagonist against
hepatic ischaemia-reperfusion injury in rats. J Hepatol.
40:934–941. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Atkinson C, He S, Morris K, Qiao F, Casey
S, Goddard M and Tomlinson S: Targeted complement inhibitors
protect against posttransplant cardiac ischemia and reperfusion
injury and reveal an important role for the alternative pathway of
complement activation. J Immunol. 185:7007–7013. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Marshall KM, He S, Zhong Z, Atkinson C and
Tomlinson S: Dissecting the complement pathway in hepatic injury
and regeneration with a novel protective strategy. J Exp Med.
211:1793–1805. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Montalvo-Jave EE, Escalante-Tattersfield
T, Ortega-Salgado JA, Piña E and Geller DA: Factors in the
pathophysiology of the liver ischemia-reperfusion injury. J Surg
Res. 147:153–159. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Quesnelle KM, Bystrom PV and
Toledo-Pereyra LH: Molecular responses to ischemia and reperfusion
in the liver. Arch Toxicol. 89:651–657. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Klune JR and Tsung A: Molecular biology of
liver ischemia-reperfusion injury: Established mechanisms and
recent advancements. Surg Clin North Am. 90:665–677.
2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ye J, Xue M, Liu Y, Zhu S, Li Y, Liu X,
Cai D, Rui J and Zhang L: Diosbulbin B-induced
mitochondria-dependent apoptosis in L-02 hepatocytes is regulated
by reactive oxygen species-mediated autophagy. Front Pharmacol.
10(676)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chavez-Cartaya R, Jamieson NV, Ramirez P,
Marin J and Pino-Chavez G: Free radical scavengers to prevent
reperfusion injury following warm liver ischemia. Transplant Proc.
31:2439–2440. 1999.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cheng Y and Rong J: Therapeutic potential
of heme oxygenase-1-carbon monoxide system against
ischemia-reperfusion injury. Curr Pharm Des. 23:3884–3898.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li JY, Gu X, Zhang WH, Jia S and Zhou Y:
GdCl3 abates hepatic ischemia-reperfusion injury by inhibiting
apoptosis in rats. Hepatobiliary Pancreat Dis Int. 8:518–523.
2009.PubMed/NCBI
|
|
19
|
Oliveira THC, Marques PE, Proost P and
Teixeira MMM: Neutrophils: A cornerstone of liver ischemia and
reperfusion injury. Lab Invest. 98:51–62. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sun L, Wu Q, Nie Y, Cheng N, Wang R, Wang
G, Zhang D, He H, Ye RD and Qian F: A role for MK2 in enhancing
neutrophil-derived ROS production and aggravating liver
ischemia-reperfusion injury. Front Immunol. 9(2610)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jaeschke H, Farhood A and Smith CW:
Neutrophils contribute to ischemia/reperfusion injury in rat liver
in vivo. FASEB J. 4:3355–3359. 1990.PubMed/NCBI
|
|
22
|
Jaeschke H, Bautista AP, Spolarics Z and
Spitzer JJ: Superoxide generation by Kupffer cells and priming of
neutrophils during reperfusion after hepatic ischemia. Free Radic
Res Commun. 15:277–284. 1991.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Woodcock SA, Kyriakides C, Wang Y, Austen
WG Jr, Moore FD Jr, Valeri R, Hartwell D and Hechtman HB: Soluble
P-selectin moderates complement dependent injury. Shock.
14:610–615. 2000.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pemberton M, Anderson G, Vetvicka V,
Justus DE and Ross GD: Microvascular effects of complement blockade
with soluble recombinant CR1 on ischemia/reperfusion injury of
skeletal muscle. J Immunol. 150:5104–5113. 1993.PubMed/NCBI
|
|
25
|
Panagiotou A, Trendelenburg M and Osthoff
M: The lectin pathway of complement in myocardial
ischemia/reperfusion injury-review of its significance and the
potential impact of therapeutic interference by C1 esterase
inhibitor. Front Immunol. 9(1151)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Arumugam TV, Magnus T, Woodruff TM,
Proctor LM, Shiels IA and Taylor SM: Complement mediators in
ischemia-reperfusion injury. Clin Chim Acta. 374:33–45.
2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Schieferdecker HL, Schlaf G, Jungermann K
and Götze O: Functions of anaphylatoxin C5a in rat liver: Direct
and indirect actions on nonparenchymal and parenchymal cells. Int
Immunopharmacol. 1:469–481. 2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wiese AV, Ender F, Quell KM, Antoniou K,
Vollbrandt T, Konig P, Kohl J and Laumonnier Y: The C5a/C5aR1 axis
controls the development of experimental allergic asthma
independent of LysM-expressing pulmonary immune cells. PLoS One.
12(e0184956)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Guo RF and Ward PA: Role of C5a in
inflammatory responses. Annu Rev Immunol. 23:821–852.
2005.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Winwood PJ and Arthur MJ: Kupffer cells:
Their activation and role in animal models of liver injury and
human liver disease. Semin Liver Dis. 13:50–59. 1993.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang LY, Zhan DL, Chen YY, Wang WH, He
CY, Lin Y, Lin YC and Lin ZN: Aflatoxin B1 enhances pyroptosis of
hepatocytes and activation of Kupffer cells to promote liver
inflammatory injury via dephosphorylation of cyclooxygenase-2: An
in vitro, ex vivo and in vivo study. Arch Toxicol. 93:3305–3320.
2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yu Y, Zhong J, Peng L, Wang B, Li S, Huang
H, Deng Y, Zhang H, Yang R, Wang C, et al: Tacrolimus downregulates
inflammation by regulating pro-/anti-inflammatory responses in
LPS-induced keratitis. Mol Med Rep. 16:5855–5862. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhou W, Farrar CA, Abe K, Pratt JR, Marsh
JE, Wang Y, Stahl GL and Sacks SH: Predominant role for C5b-9 in
renal ischemia/reperfusion injury. J Clin Invest. 105:1363–1371.
2000.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Vollmar B, Menger MD, Glasz J, Leiderer R
and Messmer K: Impact of leukocyte-endothelial cell interaction in
hepatic ischemia-reperfusion injury. Am J Physiol. 267:G786–G793.
1994.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang L, Vijayan V, Jang MS, Thorenz A,
Greite R, Rong S, Chen R, Shushakova N, Tudorache I, Derlin K, et
al: Labile heme aggravates renal inflammation and complement
activation after ischemia reperfusion injury. Front Immunol.
10(2975)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lai W, Xie X, Zhang X, Wang Y, Chu K,
Brown J, Chen L and Hong G: Inhibition of complement drives
increase in early growth response proteins and neuroprotection
mediated by Salidroside after cerebral ischemia. Inflammation.
41:449–463. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Schönermark M, Deppisch R, Riedasch G,
Rother K and Hänsch GM: Induction of mediator release from human
glomerular mesangial cells by the terminal complement components
C5b-9. Int Arch Allergy Appl Immunol. 96:331–337. 1991.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hattori R, Hamilton KK, McEver RP and Sims
PJ: Complement proteins C5b-9 induce secretion of high molecular
weight multimers of endothelial von Willebrand factor and
translocation of granule membrane protein GMP-140 to the cell
surface. J Biol Chem. 264:9053–9060. 1989.PubMed/NCBI
|
|
39
|
Fondevila C, Shen XD, Tsuchihashi S,
Uchida Y, Freitas MC, Ke B, Busuttil RW and Kupiec-Weglinski JW:
The membrane attack complex (C5b-9) in liver cold ischemia and
reperfusion injury. Liver Transpl. 14:1133–1141. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
40
|
He S, Atkinson C, Evans Z, Ellett JD,
Southwood M, Elvington A, Chavin KD and Tomlinson S: A role for
complement in the enhanced susceptibility of steatotic livers to
ischemia and reperfusion injury. J Immuno. l183:4764–4772.
2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Mao SA, Glorioso JM and Nyberg SL: Liver
regeneration. Transl Res. 163:352–362. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ibrahim S and Weiss TS: Augmenter of liver
regeneration: Essential for growth and beyond. Cytokine Growth
Factor Rev. 45:65–80. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tao Y, Wang M, Chen E and Tang H: Liver
regeneration. Mediators Inflamm. 2017(4256352)2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Sergeeva O, Sviridov E and Zatsepin T:
Noncoding RNA in liver regeneration-from molecular mechanisms to
clinical implications. Semin Liver Dis. 40:70–83. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Szijártó A and Fülöp A: Triggered liver
regeneration: From experimental model to clinical implications.
European surgical research. Eur Surg Res. 54:148–161.
2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mohammed FF and Khokha R: Thinking outside
the cell: Proteases regulate hepatocyte division. Trends Cell Biol.
15:555–563. 2005.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Jia C: Advances in the regulation of liver
regeneration. Expert Rev Gastroenterol Hepatol. 5:105–121.
2011.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Michalopoulos GK: Liver regeneration. J
Cell Physiol. 213:286–300. 2007.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Fausto N and Riehle KJ: Mechanisms of
liver regeneration and their clinical implications. J Hepatobiliary
Pancreat Surg. 12:181–189. 2005.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Strey CW, Markiewski M, Mastellos D,
Tudoran R, Spruce LA, Greenbaum LE and Lambris JD: The
proinflammatory mediators C3a and C5a are essential for liver
regeneration. J Exp Med. 198:913–923. 2003.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Markiewski MM, Mastellos D, Tudoran R,
DeAngelis RA, Strey CW, Franchini S, Wetsel RA, Erdei A and Lambris
JD: C3a and C3b activation products of the third component of
complement (C3) are critical for normal liver recovery after toxic
injury. J Immunol. 173:747–754. 2004.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Mastellos D, Papadimitriou JC, Franchini
S, Tsonis PA and Lambris JD: A novel role of complement: Mice
deficient in the fifth component of complement (C5) exhibit
impaired liver regeneration. J Immunol. 166:2479–2486.
2001.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Clark A, Weymann A, Hartman E, Turmelle Y,
Carroll M, Thurman JM, Holers VM, Hourcade DE and Rudnick DA:
Evidence for non-traditional activation of complement factor C3
during murine liver regeneration. Mol Immunol. 45:3125–3132.
2008.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Daveau M, Benard M, Scotte M, Schouft MT,
Hiron M, Francois A, Salier JP and Fontaine M: Expression of a
functional C5a receptor in regenerating hepatocytes and its
involvement in a proliferative signaling pathway in rat. J Immunol.
173:3418–3424. 2004.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Castellano G, Franzin R, Sallustio F,
Stasi A, Banelli B, Romani M, De Palma G, Lucarelli G, Divella C,
Battaglia M, et al: Complement component C5a induces aberrant
epigenetic modifications in renal tubular epithelial cells
accelerating senescence by Wnt4/βcatenin signaling after
ischemia/reperfusion injury. Aging (Albany NY). 11:4382–4406.
2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
He S, Atkinson C, Qiao F, Cianflone K,
Chen X and Tomlinson S: A complement-dependent balance between
hepatic ischemia/reperfusion injury and liver regeneration in mice.
J Clin Invest. 119:2304–2316. 2009.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Song H, He C, Knaak C, Guthridge JM,
Holers VM and Tomlinson S: Complement receptor 2-mediated targeting
of complement inhibitors to sites of complement activation. J Clin
Invest. 111:1875–1885. 2003.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Alawieh A, Langley EF, Weber S, Adkins D
and Tomlinson S: Identifying the role of complement in triggering
neuroinflammation after traumatic brain injury. J Neurosci.
38:2519–2532. 2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Schnabolk G, Parsons N, Obert E, Annamalai
B, Nasarre C, Tomlinson S, Lewin AS and Rohrer B: Delivery of
CR2-fH using AAV vector therapy as treatment strategy in the mouse
model of choroidal neovascularization. Mol Ther Methods Clin Dev.
9:1–11. 2017.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Parsons N, Annamalai B, Obert E, Schnabolk
G, Tomlinson S and Rohrer B: Inhibition of the alternative
complement pathway accelerates repair processes in the murine model
of choroidal neovascularization. Mol Immunol. 108:8–12.
2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Banda N, Levitt B, Glogowska M, Thurman J,
Takahashi K, Stahl G, Tomlinson S, Arend W and Holers V: Targeted
inhibition of the complement alternative pathway with complement
receptor 2 and factor H attenuates collagen antibody-induced
arthritis in mice. J Immunol. 183:5928–5937. 2009.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Wang B, Xu H, Li J, Gao HM, Xing YH, Lin
Z, Li HJ, Wang YQ and Cao SH: Complement depletion with cobra venom
factor alleviates acute hepatic injury induced by
ischemia-reperfusion. Mol Med Rep. 18:4523–4529. 2018.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Lehmann TG, Koeppel TA, Münch S, Heger M,
Kirschfink M, Klar E and Post S: Impact of inhibition of complement
by sCR1 on hepatic microcirculation after warm ischemia. Microvasc
Res. 62:284–292. 2001.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Heijnen BH, Straatsburg IH, Padilla ND,
Van Mierlo GJ, Hack CE and Van Gulik TM: Inhibition of classical
complement activation attenuates liver ischaemia and reperfusion
injury in a rat model. Clin Exp Immunol. 143:15–23. 2006.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Bongoni A, Lu B, Salvaris E, Roberts V,
Fang D, McRae J, Fisicaro N, Dwyer K and Cowan P: Overexpression of
human CD55 and CD59 or treatment with human CD55 protects against
renal ischemia-reperfusion injury in mice. J Immunol.
198:4837–4845. 2017.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Zhang J, Hu W, Xing W, You T, Xu J, Qin X
and Peng Z: The protective role of CD59 and pathogenic role of
complement in hepatic ischemia and reperfusion injury. Am J Pathol.
179:2876–2884. 2011.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Mastaglio S, Ruggeri A, Risitano AM,
Angelillo P, Yancopoulou D, Mastellos DC, Huber-Lang M, Piemontese
S, Assanelli A, Garlanda C, et al: The first case of COVID-19
treated with the complement C3 inhibitor AMY-101. Clin Immunol.
215(108450)2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Wang Y, Johnston K, Popoff E, Myren KJ,
Cheung A, Faria C and Tomazos I: A US cost-minimization model
comparing ravulizumab versus eculizumab for the treatment of
atypical hemolytic uremic syndrome. J Med Econ. 10:1–13.
2020.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Peipert JD, Kulasekararaj AG, Gaya A,
Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, Ojeda Gutierrez E,
Martens C, Sparling A, Webster KA, et al: Patient preferences and
quality of life implications of ravulizumab (every 8 weeks) and
eculizumab (every 2 weeks) for the treatment of paroxysmal
nocturnal hemoglobinuria. PLoS One. 15(e0237497)2020.PubMed/NCBI View Article : Google Scholar
|
